37,700 Shares in Septerna, Inc. $SEPN Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC bought a new stake in Septerna, Inc. (NASDAQ:SEPN) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 37,700 shares of the company’s stock, valued at approximately $906,000. Renaissance Technologies LLC owned about 0.08% of Septerna as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Goldman Sachs Group Inc. grew its stake in shares of Septerna by 86.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock worth $75,698,000 after acquiring an additional 1,260,409 shares in the last quarter. First Light Asset Management LLC bought a new stake in shares of Septerna in the fourth quarter worth $17,308,000. Primecap Management Co. CA bought a new stake in shares of Septerna in the fourth quarter worth $15,225,000. Perceptive Advisors LLC acquired a new position in Septerna during the second quarter worth $5,723,000. Finally, VR Adviser LLC bought a new position in Septerna in the second quarter valued at $5,713,000.

Key Septerna News

Here are the key news stories impacting Septerna this week:

• Positive Sentiment: HC Wainwright significantly improved its Septerna earnings outlook, reducing its projected FY2026 loss to $1.15 per share from $2.17 and its FY2027 loss to $1.41 from $3.21. The firm retained a “Buy” rating and a $60 price target, suggesting analysts expect improved financial performance. HC Wainwright forecasts strong price appreciation for Septerna
• Positive Sentiment: HC Wainwright also raised its quarterly 2026 and 2027 EPS forecasts, with projected losses narrowing across every period. The revisions indicate better-than-expected operating trends or a more favorable development outlook for the clinical-stage biotechnology company. HC Wainwright earnings estimate revisions
• Positive Sentiment: JonesTrading raised its price target from $43 to $62 and assigned a “Buy” rating, while Wells Fargo increased its target from $48 to $50 and maintained an “Overweight” rating. These actions reinforce a favorable Wall Street view following Septerna’s recent earnings beat. JonesTrading raises Septerna price target
• Positive Sentiment: Septerna’s latest quarterly results exceeded expectations: the company reported a $0.29-per-share loss versus the anticipated $0.43 loss, while revenue of $26.75 million topped the $19.22 million consensus estimate. Septerna shares rise on better-than-expected earnings
• Negative Sentiment: COO Elizabeth Bhatt sold 25,000 shares for approximately $1.1 million at an average price of $44, reducing her ownership by 12.55%. She still holds 174,209 shares, but the insider sale could weigh on sentiment—particularly after the stock’s strong recent advance. Septerna COO insider share sale

Analyst Ratings Changes

A number of equities analysts have recently commented on SEPN shares. Guggenheim increased their price objective on shares of Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research note on Tuesday. Truist Financial upped their target price on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research note on Friday, July 17th. Stifel Nicolaus set a $49.00 price objective on Septerna in a research note on Tuesday. Finally, Wells Fargo & Company raised their target price on shares of Septerna from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Septerna has a consensus rating of “Moderate Buy” and a consensus target price of $51.33.

Insider Activity at Septerna

In other news, insider Samira Shaikhly sold 11,798 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total transaction of $354,647.88. Following the completion of the sale, the insider owned 793 shares in the company, valued at $23,837.58. The trade was a 93.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Elizabeth Bhatt sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total value of $1,100,000.00. Following the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $7,665,196. This represents a 12.55% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 72,828 shares of company stock worth $2,684,314. Insiders own 5.80% of the company’s stock.

Septerna Trading Down 1.4%

Shares of NASDAQ SEPN opened at $44.50 on Friday. The company has a market capitalization of $2.08 billion, a P/E ratio of -82.41 and a beta of 2.29. Septerna, Inc. has a 12 month low of $10.74 and a 12 month high of $51.10. The stock has a 50 day moving average of $35.83 and a 200-day moving average of $29.64.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.14. The firm had revenue of $26.75 million for the quarter, compared to the consensus estimate of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. Analysts predict that Septerna, Inc. will post -1.32 EPS for the current fiscal year.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.